Stocktoria
AstraZeneca PLC AZN.ST
AstraZeneca PLC statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($67.95); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
AstraZeneca PLC trades at about 284.9× earnings — below its 10-year norm (10-year range 252.2×–646×, median 365.6×).
Shaded band = 10-year range (252.2×–646×); dot = today's 284.9×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 81.9% | 81.1% | 82.0% | 72.1% |
| Operating margin | 22.7% | 19.0% | 19.0% | 10.2% |
| Net margin | 17.4% | 13.0% | 13.0% | 7.4% |
| FCF margin | 14.8% | 13.5% | 14.3% | 16.3% |
| Return on assets | 9.0% | 6.8% | 5.9% | 3.4% |
| Return on equity | 21.0% | 17.2% | 15.2% | 8.9% |
| Debt / equity | 0.51× | 0.65× | 0.57× | 0.62× |
| Current ratio | 0.94 | 0.93 | 0.82 | 0.86 |
Computed from company filings · SE · as of 2025-12-31. Figures in USD. Facts plus Stocktoria's own computed scores — not investment advice.